Search Thermo Fisher Scientific
Rely on NGS for solid tumor genomic profiling
The number of molecular biomarkers relevant for precision oncology research is rapidly growing across solid tumors, and in many cases sequential single-gene testing methods do not yield desired results in time or for only a limited number of biomarkers. Therefore, next-generation sequencing (NGS) has become a technology of choice in precision oncology research for genomic profiling from formalin-fixed paraffin-embedded (FFPE) tissue or liquid biopsy samples*.
Oncomine solutions for FFPE tissue testing
Choose from targeted to comprehensive solid tumor ngs solutions.
Oncomine Precision Assay (50 genes) |
Oncomine Comprehensive Assay V3 (161 genes) |
Oncomine Comprehensive Assay Plus (517 genes) |
| Rapid detection of relevant biomarkers for NSCLC, melanoma, colon, thyroid, and cholangiocarcinoma, and majority of biomarkers relevant in other tumor types | Rapid detection of relevant biomarkers for majority of solid tumors including breast and prostate cancer, and HRR genes, tumor suppressor genes, such as POLE and MDM, amongst others | Comprehensive genomic profiling (CGP) with relevant biomarkers for the majority of solid tumors, including ovarian, and gene signatures, including homologous recombination deficiency (HRD), tumor mutational burden (TMB), and microsatellite instability (MSI) |
| Turnaround time (TAT) as little as 24 hours | Turnaround time (TAT) as little as 26 hours | Turnaround time (TAT) in 3 days |
| 10 ngs of DNA/RNA, enabling more cancer research samples to be profiled | 20 ngs of DNA/RNA, enabling more cancer samples to be profiled | 20 ngs of DNA/RNA, enabling more cancer samples to be profiled |
Oncomine assays cover biomarkers across multiple solid tumors and enable labs to choose the most efficient tool for each tumor sample.
Multi-cancer
Oncomine Precision Assay
50 genes
DNA & RNA inputs
SNVs/indels
CNVs
Fusions
Multi-cancer
Oncomine Pan-Cancer Cell-Free Assay
52 genes
DNA & RNA inputs
SNVs/nndels
Full-length APC, FBXW7,
PTEN,TP53
CNVs
Fusions
Lung
Oncomine Lung cfTNA Assay
12 genes
DNA & RNA inputs
SNVs/indels
CNVs
Fusions
Breast
Oncomine Breast cfDNA Assay v2
12 genes
SNVs/indels
CNVs
TP53
Colon
Oncomine Colon cfDNA Assay
14 genes
SNVs/indels
Explore Oncomine solutions for liquid biopsy sample testing
A diverse menu of targeted assays with multi-cancer and tumor type-specific coverage to fit your clinical research needs.
Oncomine solutions for emerging biomarker testing
Cancer research is increasingly focused on precision oncology approaches that rely on the detection of biomarkers.
Deeper knowledge of molecular pathways, their interactions, and fundamental understanding of cancer biology may elucidate the progression and help predict the response of future treatments.
Oncomine solutions provide highly automated end-to-end workflows that enable oncology biomarker detection in a broad spectrum of laboratories.
For Research Use Only. Not for use in diagnostic procedures.
*Scott JA, et al. Compromised Outcomes in Stage IV Non-Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World Data. JCO Oncol Pract. 2024 Jan;20(1):145-153.
Case Number: 61467